ORBIMED ADVISORS LLC purchased 286.7% of their position (1M shares) of SCRIBE THERAPEUTICS, INC. on the open market
Open‑market purchase worth $15.00M — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 7/29/2026ACC: 0000947871-26-000733
Director
Since Jul 2026
-716.85K
Net shares
Net seller
$15.00M
Total acquired
1
Open market trades
1B · 0S
3
Total transactions
1.35M acquired · 2.07M disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+348.82K
Price / share
—
Trade value
—
% of position
New position
7/27/2026
0.00→348.82K
Common Stock
Indirect
Shares
+1M
Price / share
$15.00
Trade value
$15M
% of position
286.7%
7/27/2026
348.82K→1.35M
Total
Net shares
+1.35M
Net value
$15M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 7/27/2026 | C · Conversion | +348.82K | — | — | New position | 0.00 | 348.82K |
| Common Stock Indirect | 7/27/2026 | P · Purchase | +1M | $15.00 | $15M | 286.7% | 348.82K | 1.35M |
| Total | +1.35M | $15M | ||||||
Derivative Transactions1
Series B Preferred Stock
Indirect
Converts to
Common Stock
348.82K shares
Shares
−2.07M
Strike price
Held after
0.00
Exercisable
—
7/27/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series B Preferred Stock Indirect | Common Stock348.82K shares | 7/27/2026 | C · Conversion | −2.07M | — | 0.00 |